Andere Sprachen EirGenix Inc.

Aktien

6589

TW0006589005

6589

Schlusskurs Taipei Exchange Andere Börsenplätze 00:00:00 31.05.2024			% 5 Tage	% 1. Jan.
80.3 ^TWD	+1.52%		+0.88%	-20.10%

15.05.	EirGenix Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
22.03.	EirGenix Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15.05.
EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22.03.
EirGenix, Inc. Resolves to Sign the Contract with Clinical CRO and the Relevant Companies for Phase III Clinical Trail of the EG1206A	08.03.
EirGenix Inc.'s Breast Cancer Biosimilar Receives Marketing Authorization by EC	23.11.
EirGenix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.
EirGenix Inc. Announces the Establishment of Phase II Facility and Production Equipment in Zhubei	09.11.
Novartis' Sandoz Unit Says European Medicines Agency Panel Supports Approval of Trastuzumab Biosimilar	18.09.23
Novartis-Krebsmedikament Trastuzumab erhält EMA-Empfehlung	18.09.23
Novartis Unit Wins European Medicines Agency's Positive Opinion for Breast Cancer Biosimilar	18.09.23
National Health Insurance Administration Approves EirGenix Inc.'S Biosimilar, Eirgasun Vial 150 Mg to Be Enrolled in the Reimbursement System	18.09.23
Sandoz erhält positive CHMP-Stellungnahme für Krebs-Biosimilar	18.09.23
EirGenix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09.08.23
EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15.05.23
EirGenix Inc. Completes the Phase 1 Clinical Trial of Its Second Breast Cancer Biosimilar EG1206A in Europe	03.05.23
EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	20.03.23
EirGenix Inc. Announces Executive Changes	10.01.23
Eirgenix Inc. Announces Establishment of Corporate Governance Committee	28.12.22
EirGenix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11.11.22
Eirgenix, Inc., Submits the Biosimilar Drug Eirgasum of 150 Mg Powder for Concentratefor Solution for Infusion Presentation New Drug Application to the Taiwan Food and Drug Administration	30.09.22
EirGenix Inc. Appoints Po-Chih Chen as Remuneration Committee	08.09.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen EirGenix Inc.

Aktien

6589

TW0006589005

6589

Andere Sprachen

Filter